Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors

Front Immunol. 2019 Mar 12:10:407. doi: 10.3389/fimmu.2019.00407. eCollection 2019.

Abstract

In order to compensate for the increased oxygen consumption in growing tumors, tumors need angiogenesis and vasculogenesis to increase the supply. Insufficiency in this process or in the microcirculation leads to hypoxic tumor areas with a significantly reduced pO2, which in turn leads to alterations in the biology of cancer cells as well as in the tumor microenvironment. Cancer cells develop more aggressive phenotypes, stem cell features and are more prone to metastasis formation and migration. In addition, intratumoral hypoxia confers therapy resistance, specifically radioresistance. Reactive oxygen species are crucial in fixing DNA breaks after ionizing radiation. Thus, hypoxic tumor cells show a two- to threefold increase in radioresistance. The microenvironment is enriched with chemokines (e.g., SDF-1) and growth factors (e.g., TGFβ) additionally reducing radiosensitivity. During recent years hypoxia has also been identified as a major factor for immune suppression in the tumor microenvironment. Hypoxic tumors show increased numbers of myeloid derived suppressor cells (MDSCs) as well as regulatory T cells (Tregs) and decreased infiltration and activation of cytotoxic T cells. The combination of radiotherapy with immune checkpoint inhibition is on the rise in the treatment of metastatic cancer patients, but is also tested in multiple curative treatment settings. There is a strong rationale for synergistic effects, such as increased T cell infiltration in irradiated tumors and mitigation of radiation-induced immunosuppressive mechanisms such as PD-L1 upregulation by immune checkpoint inhibition. Given the worse prognosis of patients with hypoxic tumors due to local therapy resistance but also increased rate of distant metastases and the strong immune suppression induced by hypoxia, we hypothesize that the subgroup of patients with hypoxic tumors might be of special interest for combining immune checkpoint inhibition with radiotherapy.

Keywords: T cells; Tregs; cancer; hypoxia; immune checkpoint inhibition; immunotherapy; radiotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use*
  • Chemokines / immunology
  • Combined Modality Therapy
  • Humans
  • Hypoxia / pathology*
  • Immunotherapy / methods*
  • Intercellular Signaling Peptides and Proteins / metabolism
  • Lymphocyte Activation / immunology
  • Myeloid-Derived Suppressor Cells / immunology
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Oxygen Consumption / physiology
  • Radiation Tolerance / physiology*
  • Radiation, Ionizing
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Regulatory / immunology
  • Tumor Microenvironment / immunology

Substances

  • Antineoplastic Agents, Immunological
  • Chemokines
  • Intercellular Signaling Peptides and Proteins